Paclitaxel plus cisplatin vs. 5-fluorouracil plus cisplatin as first-line treatment for patients with advanced squamous cell esophageal cancer

American Journal of Cancer Research

Volumn 6, Issue 10, 2016, Pages 2345-2350

  Liu, Ying ^a   Ren, Zhonghai ^b   Yuan, Long ^a   Xu, Shuning ^a   Yao, Zhihua ^a   Qiao, Lei ^a   Li, Ke ^a  

^a ZHENGZHOU UNIVERSITY   (China)

^b Department of Medical Oncology of Nanyang City Center Hospital ^*  (China)

Author keywords

5 fluorouracil; Cisplatin; First line treatment; Paclitaxel; Squamous cell esophageal cancer

Indexed keywords

CISPLATIN; FLUOROURACIL; PACLITAXEL;

ADULT; AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CONTINUOUS INFUSION; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FATIGUE; FEMALE; HUMAN; LEUKOPENIA; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; VOMITING;

EID: 84995603559     PISSN: None     EISSN: 21566976     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Herszenyi L and Tulassay Z. Epidemiology of gastrointestinal and liver tumors. Eur Rev Med Pharmacol Sci 2010; 14: 249-258
2. Wang AH, Liu Y, Wang B, He YX, Fang YX and Yan YP. Epidemiological studies of esophageal cancer in the era of genome-wide association studies. World J Gastrointest Pathophysiol 2014; 5: 335-343
3. Mariette C, Balon JM, Piessen G, Fabre S, Van Seuningen I and Triboulet JP. Pattern of recurrence following complete resection of esophageal carcinoma and factors predictive of recurrent disease. Cancer 2003; 97: 1616-1623
4. Nakagawa S, Kanda T, Kosugi S, Ohashi M, Suzuki T and Hatakeyama K. Recurrence pattern of squamous cell carcinoma of the thoracic esophagus after extended radical esophagectomy with three-field lymphadenectomy. J Am Coll Surg 2004; 198: 205-211
5. Vestermark LW, Sorensen P and Pfeiffer P. [Chemotherapy to patients with metastatic carcinoma of the esophagus and gastro-esophageal junction. A survey of a Cochrane review]. Ugeskr Laeger 2008; 170: 633-636
6. Bleiberg H, Conroy T, Paillot B, Lacave AJ, Blijham G, Jacob JH, Bedenne L, Namer M, De Besi P, Gay F, Collette L and Sahmoud T. Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. Eur J Cancer 1997; 33: 1216-1220
7. Hayashi K, Ando N, Watanabe H, Ide H, Nagai K, Aoyama N, Takiyama W, Ishida K, Isono K, Makuuchi H, Imamura M, Shinoda M, Ikeuchi S, Kabuto T, Yamana H and Fukuda H. Phase II evaluation of protracted infusion of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG) Trial (JCOG9407). Jpn J Clin Oncol 2001; 31: 419-423
8. Lorenzen S, Schuster T, Porschen R, Al-Batran SE, Hofheinz R, Thuss-Patience P, Moehler M, Grabowski P, Arnold D, Greten T, Muller L, Rothling N, Peschel C, Langer R and Lordick F. Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol 2009; 20: 1667-1673
9. Ajani JA, Ilson DH, Daugherty K, Pazdur R, Lynch PM and Kelsen DP. Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst 1994; 86: 1086-1091
10. Ilson DH, Wadleigh RG, Leichman LP and Kelsen DP. Paclitaxel given by a weekly 1-h infusion in advanced esophageal cancer. Ann Oncol 2007; 18: 898-902
11. Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, Hironaka S, Sugimoto N, Lipatov O, Kim TY, Cunningham D, Rougier P, Komatsu Y, Ajani J, Emig M, Carlesi R, Ferry D, Chandrawansa K, Schwartz JD and Ohtsu A. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 2014; 15: 1224-1235
12. Petrasch S, Welt A, Reinacher A, Graeven U, Konig M and Schmiegel W. Chemotherapy with cisplatin and paclitaxel in patients with locally advanced, recurrent or metastatic oesophageal cancer. Br J Cancer 1998; 78: 511-514
13. Ilson DH, Forastiere A, Arquette M, Costa F, Heelan R, Huang Y and Kelsen DP. A phase II trial of paclitaxel and cisplatin in patients with advanced carcinoma of the esophagus. Cancer J 2000; 6: 316-323
14. Zhang X, Shen L, Li J, Li Y, Li J and Jin M. A phase II trial of paclitaxel and cisplatin in patients with advanced squamous-cell carcinoma of the esophagus. Am J Clin Oncol 2008; 31: 29-33
15. Huang J, Zhou Y, Zhang H, Qu T, Mao Y, Zhu H, Quan L, Xing P, Wang J, He J, Xu N and Sun Y. A phase II study of biweekly paclitaxel and cisplatin chemotherapy for recurrent or metastatic esophageal squamous cell carcinoma: ERCC1 expression predicts response to chemotherapy. Med Oncol 2013; 30: 343
16. Cao W, Xu C, Lou G, Jiang J, Zhao S, Geng M, Xi W, Li H and Jin Y. A phase II study of paclitaxel and nedaplatin as first-line chemotherapy in patients with advanced esophageal cancer. Jpn J Clin Oncol 2009; 39: 582-587
17. He YF, Ji CS, Hu B, Fan PS, Hu CL, Jiang FS, Chen J, Zhu L, Yao YW and Wang W. A phase II study of paclitaxel and nedaplatin as front-line chemotherapy in Chinese patients with metastatic esophageal squamous cell carcinoma. World J Gastroenterol 2013; 19: 5910-5916
18. Du J, Hu C, Zhang Y, Hu B, Wang F and Zhang Y. A retrospective study of paclitaxel combining nedaplatin chemotherapy for esophageal cancer. Anticancer Drugs 2015; 26: 101-105